Cargando…
The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
Diffuse malignant mesothelioma (DMM) is one of the prognostically most discouraging cancers with median survivals of only 12–22 months. Due to its insidious onset and delayed detection, DMM is often at an advanced stage at diagnosis and is considered incurable. Combined chemo- and radiotherapy follo...
Autores principales: | Schürch, Christian M., Forster, Stefan, Brühl, Frido, Yang, Sara H., Felley-Bosco, Emanuela, Hewer, Ekkehard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739575/ https://www.ncbi.nlm.nih.gov/pubmed/29296529 http://dx.doi.org/10.1080/2162402X.2017.1373235 |
Ejemplares similares
-
Don't eat me/eat me signals as a novel strategy in cancer immunotherapy
por: Khalaji, Amirreza, et al.
Publicado: (2023) -
Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015) -
Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma
por: Kazama, Ryo, et al.
Publicado: (2020) -
A combined “eat me/don’t eat me” strategy based on extracellular vesicles for anticancer nanomedicine
por: Belhadj, Zakia, et al.
Publicado: (2020) -
The biology of the tumor microenvironment in DLBCL: Targeting the “don’t eat me” signal
por: Ennishi, Daisuke
Publicado: (2021)